Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Venetoclax-based combinations in patients with accelerated and blast-phase MPNs

Raajit Rampal • 26 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Ruxolitinib Venetoclax

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly comments on the use of venetoclax-based combinations in patients with accelerated and blast-phase myeloproliferative neoplasms (MPNs) and the need to further evaluate the best approach to using these combinations. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Raajit Rampal

Interferon in PV and ET: unanswered questions 0:45
Interferon in PV and ET: unanswered questions
Raajit Rampal • 24 Aug 2024
The evolving treatment landscape in PV 0:56
The evolving treatment landscape in PV
Raajit Rampal • 24 Aug 2024
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models 1:27
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
Raajit Rampal • 24 Aug 2024
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors 0:34
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors
Raajit Rampal • 14 Jun 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals